Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
about
Micronutrients in Oncological InterventionMolecular Targeted Intervention for Pancreatic CancerTreatment of Pancreatic Cancer with Pharmacological AscorbateIncreasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular AscorbateSOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathwaysAntioxidants in Translational MedicineHigh-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trialThe isoprostanes--25 years laterRecent treatment advances and novel therapies in pancreas cancer: a review.Iron and thiols as two major players in carcinogenesis: friends or foes?The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life.Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.Intravenous Vitamin C and Cancer: A Systematic Review.Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.Optimizing production of Fc-amidated peptides by Chinese hamster ovary cellsPeroxiporin Expression Is an Important Factor for Cancer Cell Susceptibility to Therapeutic H2O2: Implications for Pharmacological Ascorbate Therapy.Anticancer therapeutic potential of Mn porphyrin/ascorbate systemFluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based TherapyDirect spectrophotometric measurement of supra-physiological levels of ascorbate in plasma.Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generationParenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy.Myths, artifacts, and fatal flaws: identifying limitations and opportunities in vitamin C research.Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer.Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal CancerThe ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines.The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies.Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment.Simple biological systems for assessing the activity of superoxide dismutase mimics.A rational approach for improving the ascorbate antineoplastic activity.Molecular mechanisms of pharmacological doses of ascorbate on cancer cells.The unpaved journey of vitamin C in cancer treatment.Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.Prevention and treatment of cancers by immune modulating nutrients.Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer.
P2860
Q26764839-8D945720-A413-43DF-AF61-53B02EFE1657Q26798453-D9AA5039-3666-4AA5-8A24-AE60012EEE67Q26800853-E909DCCE-5CE8-4F00-9DBD-9E07AAFB838CQ27021794-5B6AB3A7-45D4-4D17-BCE4-13124934BA03Q28385000-3A44CCF0-155E-4A9B-ABD8-E400427670B6Q28394550-BD290731-BA85-4C63-A506-86078FC14513Q28545827-A7088A73-E34D-4E8F-9DF6-A613862AB403Q33601352-0C5C0AEC-BE2E-448D-B5C0-A4BF1C80BB6AQ33625168-E0A938C9-6288-4F9F-B49E-AD847E786266Q34042006-3116B3E9-BBE7-4EC8-919B-056E9A598B5CQ34349450-B2A2786E-341F-4926-BC95-E86CCC6EE5F2Q34458788-AFC53640-DE9B-4FB5-B9C4-4F30DB86D6C1Q35175163-5B04642A-9B25-49EC-9227-0EA70FDD09ECQ35496324-7C368946-74EE-4023-9E4E-090B5CDE1892Q35639007-106B2045-F0BF-4EEF-ADA0-49B6A4F444C3Q35811216-03D38251-36FC-4F97-BD78-7528C5C9287BQ36255595-D7BB171B-B47D-49AC-8DF5-3E351AD95BF7Q36386390-3BDC031E-7A40-4C79-BFE2-22E061CB7761Q36483845-ABA06FDC-A4DE-4E90-BEC9-9E95EA371FB4Q36647008-6D28113A-DEC3-49F4-A2CB-E7449B44DD2EQ36653423-A17AF0B2-447C-41CE-80CE-A013E3B37B74Q37049935-31329171-974E-4E22-BFBA-C227C0070C78Q37100095-25C7EFE0-A98E-4788-962C-F5E8D4603A26Q37406743-61321B73-FAD0-466D-B258-891966B21FFAQ37409942-17682685-5FB9-4D41-AC4F-1CEDF8FD2F19Q37420554-6B38BB8A-FB03-4DD8-8BB1-CA6DA03F4EBCQ37435134-E8E8E0C3-F278-4D5D-9545-645EAEDDA887Q37550889-15909B73-E71E-4269-9B21-D595AAEFD881Q37638916-99ECEEEA-19F4-4B78-BA55-597591A30DE4Q37701328-7F0E32D0-1D6C-4ACF-B923-DEE8E28EFE6FQ37729938-40BCF028-43C6-4EEA-B15D-B124F44F83CDQ37734019-44C328E8-E477-4B99-B525-8A4255112728Q38185439-A329E2F8-4B55-4C63-BACC-6E63DE0377CEQ38525077-1F3B1577-6FE8-4B7D-BD40-BB73CE8C5D7FQ38561256-A368A016-7812-4683-BF6A-9A083118AC91Q38622264-5B43A2C5-DB5A-47DA-BC5A-AA4343214BCEQ38633074-8C3D89BA-06D2-4974-B758-264690D60B40Q38709364-F99F6B61-6D3B-4A14-97A6-50B8F62B6D70Q38718929-27F8E30A-81DA-4934-9FA8-C860D19E8A89Q38863198-10E20D69-037A-407A-AA68-20FC5E2E1FA6
P2860
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacological ascorbate with ...... from a phase I clinical trial.
@ast
Pharmacological ascorbate with ...... from a phase I clinical trial.
@en
type
label
Pharmacological ascorbate with ...... from a phase I clinical trial.
@ast
Pharmacological ascorbate with ...... from a phase I clinical trial.
@en
prefLabel
Pharmacological ascorbate with ...... from a phase I clinical trial.
@ast
Pharmacological ascorbate with ...... from a phase I clinical trial.
@en
P2093
P2860
P50
P1476
Pharmacological ascorbate with ...... from a phase I clinical trial
@en
P2093
B A Wagner
L J Roberts
T R Halfdanarson
P2860
P2888
P304
P356
10.1007/S00280-013-2070-8
P577
2013-02-05T00:00:00Z